In the setting of recurrent prostate cancer, Ramalingam et al [44] published a small series on 18 patients with a mean follow-up period of 10.0 months, obtaining a significant reduction of PSA values and a complete response rate of 88.9% with only four patients experiencing minor adverse events. Here, KLK3 is linked to prostate carcinoma.